Literature DB >> 23495879

Surgical outcomes in recurrent glioma: clinical article.

Jason M Hoover1, Macaulay Nwojo, Ross Puffer, Jay Mandrekar, Fredric B Meyer, Ian F Parney.   

Abstract

OBJECT: The object of this study was to assess outcomes after surgery for recurrent intracranial glioma.
METHODS: The authors retrospectively reviewed cases involving adult patients with intracranial glioma patients undergoing initial surgery (biopsy or resection) and one or more additional surgeries at their institution.
RESULTS: A total of 323 operations were performed in 131 patients. The median survival was 76 months after first surgery, 36 months after second, 24 months after third, and 26.5 months after 4 or more surgeries. The overall complication rate was 12.8% after first surgery, 27.0% after second (OR 2.52, p = 0.0068), 22.0% after third (OR 1.92, not statistically significant [NS]), and 22.2% after 4 or more (OR 1.95, NS). Neurological complications occurred in 4.8% of patients at first surgery, 12.1% at second (OR 2.7, p = 0.0437), 8.2% at third (OR 1.75, NS), and 11.1% at 4 or more surgeries (OR 2.4583, NS). Regional complications occurred in 6.2% after first surgery, 9.9% after second surgery (OR 2.30, p = 0.095), 13.7% after third surgery (OR 3.31, p = 0.015), and 22.2% after 4 or more surgeries (OR 5.95, p = 0.056). Systemic complications occurred in 3.2% after first surgery, in 7.3% after second surgery (OR 2.3, p = 0.NS), in 4.1% after third surgery (OR 1.3, NS), and 0% after 4 or more surgeries. Reduction in Karnofsky Performance Status score occurred in 0% after first surgery, 8.1% after second surgery (OR 3.13, p = 0.0018), 10.2% after third surgery (OR 5.52, p < 0.0001), and 11.1% after 4 or more surgeries (OR 1.037, NS).
CONCLUSIONS: Postoperative survival is relatively prolonged but complication risk increases in patients with glioma who undergo multiple cranial surgeries. The largest increase in neurological risk occurs between the first and second surgery. In contrast, regional complication risk increases consistently with each surgery. The risk of systemic complications is not significantly altered with increasing surgeries. However, these complications only result in a modestly increased risk of functional decline after 2 or more surgeries. These findings may help counsel patients considering multiple glioma surgeries.

Entities:  

Mesh:

Year:  2013        PMID: 23495879     DOI: 10.3171/2013.2.JNS121731

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study.

Authors:  Jamie J Van Gompel; Michael J Link; Jason P Sheehan; Zhiyuan Xu; David Mathieu; Hideyuki Kano; L Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2014-06-04

2.  Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients.

Authors:  Anne-Katrin Hickmann; Minou Nadji-Ohl; Nikolai J Hopf
Journal:  J Neurooncol       Date:  2015-01-04       Impact factor: 4.130

3.  The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis.

Authors:  Michael Brendan Cloney; Adam M Sonabend; Jonathan Yun; Jingyan Yang; Fabio Iwamoto; Suprit Singh; Govind Bhagat; Peter Canoll; George Zanazzi; Jeffrey N Bruce; Michael Sisti; Sameer Sheth; E Sander Connolly; Guy McKhann
Journal:  J Neurooncol       Date:  2017-01-23       Impact factor: 4.130

4.  mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells.

Authors:  Daming Zhang; Guang Yang; Xin Chen; Chunmei Li; Lu Wang; Yaohua Liu; Dayong Han; Huailei Liu; Xu Hou; Weiguang Zhang; Chenguang Li; Zhanqiang Han; Xin Gao; Shiguang Zhao
Journal:  J Mol Neurosci       Date:  2014-01-28       Impact factor: 3.444

Review 5.  Recurrent malignant gliomas.

Authors:  John P Kirkpatrick; John H Sampson
Journal:  Semin Radiat Oncol       Date:  2014-10       Impact factor: 5.934

Review 6.  Clinical trials in neurosurgical oncology.

Authors:  Meghan Murphy; Ian F Parney
Journal:  J Neurooncol       Date:  2014-08-09       Impact factor: 4.130

7.  Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

Authors:  Florian Ringel; Haiko Pape; Michael Sabel; Dietmar Krex; Hans Christoph Bock; Martin Misch; Astrid Weyerbrock; Thomas Westermaier; Christian Senft; Philippe Schucht; Bernhard Meyer; Matthias Simon
Journal:  Neuro Oncol       Date:  2015-08-04       Impact factor: 12.300

8.  Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.

Authors:  Vijay M Patil; Arti Bhelekar; Nandini Menon; Atanu Bhattacharjee; Vijai Simha; Ram Abhinav; Anuja Abhyankar; Epari Sridhar; Abhishek Mahajan; Ameya D Puranik; Nilendu Purandare; Amit Janu; Ankita Ahuja; Rahul Krishnatry; Tejpal Gupta; Rakesh Jalali
Journal:  Cancer Med       Date:  2020-05-13       Impact factor: 4.452

9.  Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature.

Authors:  Ramin A Morshed; Jacob S Young; Andrew J Gogos; Alexander F Haddad; James T McMahon; Annette M Molinaro; Vivek Sudhakar; Nadeem Al-Adli; Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  Acta Neurochir (Wien)       Date:  2021-12-30       Impact factor: 2.216

10.  BMP4, a new prognostic factor for glioma.

Authors:  Qiang Wu; Jiarui Yao
Journal:  World J Surg Oncol       Date:  2013-10-08       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.